These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6454421)

  • 1. [Antirabies treatment with Fuenzalida-Palacios type vaccine].
    Fábrega FP; Sepúlveda CA
    Bol Oficina Sanit Panam; 1981 Mar; 90(3):211-7. PubMed ID: 6454421
    [No Abstract]   [Full Text] [Related]  

  • 2. Rabies treatment with vaccine of the Fuenzalida-Palacios type.
    Fábrega FP; Sepúlveda CA
    Bull Pan Am Health Organ; 1982; 16(1):40-6. PubMed ID: 7074254
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse reactions associated with a Fuenzalida-Palacios rabies vaccine: a quasi-experimental study.
    Bonito RF; de Oliveira NM; Nishioka Sde A
    Rev Soc Bras Med Trop; 2004; 37(1):7-9. PubMed ID: 15042173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Modified Fuenzalida type antirabies vaccine (5 years of production and observation)].
    Markus HL; Jobim GO; Moura Mdo C
    Rev Inst Med Trop Sao Paulo; 1971; 13(2):114-20. PubMed ID: 5162519
    [No Abstract]   [Full Text] [Related]  

  • 5. [Thermostability of rabies vaccine, type Fuenzalida & Palacios, for human use].
    Albas A; Fuches RM; Gallina NM; Mendonça RM; Fang FL; Valentini EJ
    Rev Inst Med Trop Sao Paulo; 1992; 34(1):27-31. PubMed ID: 1284895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced schedule of human anti-rabies immunization with Fuenzalida & Palacios vaccine. Additional data.
    Favoretto SR; Carrieri ML; Tino MS; Assis A; Zanetti CR; Pereira OA
    Rev Inst Med Trop Sao Paulo; 1993; 35(3):281-4. PubMed ID: 8278759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the bacillus of Calmette-Guérin, Propionibacter acnes and avridine as immunomodulators in antirabies vaccination of mice using the Fuenzalida-Palacios mouse brain vaccine.
    Megid J; Peraçolli MT; Curi PR; Zanetti CR; Cabrera WH; Vassao R; Ito FH
    Vaccine; 1999 May; 17(19):2446-52. PubMed ID: 10392627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-mediated immune response to antirabies vaccine in man.
    Santos CM; Kimura H; Longo IM; Mendes NF; Pereira OA
    Allergol Immunopathol (Madr); 1980; 8(3):163-8. PubMed ID: 7405762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [THE "FUENZALIDA-PALACIOS" ANTIRABIES VACCINE].
    RISPOLI JA
    Sem Med; 1963 Oct; 123():1275-8. PubMed ID: 14111236
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of cytokines concentration and percentage of survival of rabies virus-infected mice submitted to anti-rabies Vero-cell propagated vaccine and P. acnes.
    Megid J; Appolinario CM; Mazzini AM; Almeida MF
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):192-6. PubMed ID: 16930720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Post-exposure antirabies prophylaxis in pregnant women].
    Figueroa Damián R; Ortiz Ibarra FJ; Arredondo García JL
    Ginecol Obstet Mex; 1994 Jan; 62():13-6. PubMed ID: 8168717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Production of vaccines in Chile, the importance of local supply].
    Ibarra M C; Parada V M
    Rev Chilena Infectol; 2020 Aug; 37(4):413-421. PubMed ID: 33399662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-exposure use of the new human diploid cell (rabies) vaccine at Clark Air Base.
    Tice AW
    Aviat Space Environ Med; 1980 Sep; 51(9 Pt 1):923-5. PubMed ID: 7417166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effect versus quality control of the Fuenzalida-Palacios antirabies vaccine.
    Nogueira YL
    Rev Inst Med Trop Sao Paulo; 1998; 40(5):295-9. PubMed ID: 10030074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of the usefulness of the antibody binding test for the estimation of the potency of the rabies vaccine].
    Wysokińska T; Janaszek W; Rymkiewicz D
    Przegl Epidemiol; 1994; 48(3):297-9. PubMed ID: 7938635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determination of the degree of antirabies immunity in mice with different capabilities for interferon formation].
    Karakuiumchian MK; Bektemirova MS; Polkovnikova VIa
    Vopr Virusol; 1973; 18(3):275-7. PubMed ID: 4769528
    [No Abstract]   [Full Text] [Related]  

  • 17. [Development of a method of inactivation of antirabies vaccine by ultraviolet rays. II. Immunogenic and antigenic properties of antirabies vaccine, inactivated by ultraviolet rays].
    PISKAREVA NA; IVANOV NP; PISAREVA NA
    Vopr Virusol; 1959; 4():615-9. PubMed ID: 14433265
    [No Abstract]   [Full Text] [Related]  

  • 18. Recommendation of the Immunization Practices Advisory Committee (ACIP). Supplementary statement on rabies vaccine and serologic testing.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1981 Oct; 30(42):535-6. PubMed ID: 6793837
    [No Abstract]   [Full Text] [Related]  

  • 19. The rabies peripheral challenge test: more accurate determination of vaccine potency.
    Wunderli PS; Dreesen DW; Miller TJ; Baer GM
    Vaccine; 2006 Nov; 24(49-50):7115-23. PubMed ID: 16919854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic value of lyophilized phenolized antirabies vaccine.
    VEERARAGHAVAN N; SUBRAHMANYAN TP
    Bull World Health Organ; 1961; 25(1):115-7. PubMed ID: 13925168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.